Is PCVX or GENB more profitable?

Generate Biomedicines' return on equity of 0.00% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -32.51% -29.51% Generate Biomedicines N/A N/A N/A

Does the media refer more to PCVX or GENB?

In the previous week, Vaxcyte had 1 more articles in the media than Generate Biomedicines. MarketBeat recorded 3 mentions for Vaxcyte and 2 mentions for Generate Biomedicines. Vaxcyte's average media sentiment score of 0.61 beat Generate Biomedicines' score of 0.00 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Generate Biomedicines 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TGTX or GENB?

In the previous week, Generate Biomedicines had 1 more articles in the media than TG Therapeutics. MarketBeat recorded 2 mentions for Generate Biomedicines and 1 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.72 beat Generate Biomedicines' score of 0.00 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Generate Biomedicines 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GENB or APGE more profitable?

Generate Biomedicines' return on equity of 0.00% beat Apogee Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Generate Biomedicines N/A N/A N/A Apogee Therapeutics N/A -32.64% -31.25%

Does the media prefer GENB or APGE?

In the previous week, Apogee Therapeutics had 4 more articles in the media than Generate Biomedicines. MarketBeat recorded 6 mentions for Apogee Therapeutics and 2 mentions for Generate Biomedicines. Apogee Therapeutics' average media sentiment score of 0.18 beat Generate Biomedicines' score of 0.00 indicating that Apogee Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Apogee Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to GENB or PTGX?

In the previous week, Protagonist Therapeutics had 2 more articles in the media than Generate Biomedicines. MarketBeat recorded 4 mentions for Protagonist Therapeutics and 2 mentions for Generate Biomedicines. Protagonist Therapeutics' average media sentiment score of 0.43 beat Generate Biomedicines' score of 0.00 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protagonist Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Generate Biomedicines (GENB) Competitors

$17.41 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$17.30 -0.11 (-0.66%)

As of 07/2/2026 07:52 PM Eastern

Compare

GENB vs. PCVX, TGTX, APGE, QGEN, and PTGX

Should you buy Generate Biomedicines stock or one of its competitors? MarketBeat compares Generate Biomedicines with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Generate Biomedicines include Vaxcyte (PCVX), TG Therapeutics (TGTX), Apogee Therapeutics (APGE), Qiagen (QGEN), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry.

How does Generate Biomedicines compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Generate Biomedicines (NASDAQ:GENB) are both mid-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

96.8% of Vaxcyte shares are held by institutional investors. 3.3% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Generate Biomedicines' return on equity of 0.00% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Generate Biomedicines	N/A	N/A	N/A

Vaxcyte presently has a consensus price target of $86.00, suggesting a potential upside of 47.29%. Generate Biomedicines has a consensus price target of $25.40, suggesting a potential upside of 45.89%. Given Vaxcyte's higher probable upside, equities research analysts clearly believe Vaxcyte is more favorable than Generate Biomedicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

In the previous week, Vaxcyte had 1 more articles in the media than Generate Biomedicines. MarketBeat recorded 3 mentions for Vaxcyte and 2 mentions for Generate Biomedicines. Vaxcyte's average media sentiment score of 0.61 beat Generate Biomedicines' score of 0.00 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Generate Biomedicines has higher revenue and earnings than Vaxcyte. Generate Biomedicines is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Generate Biomedicines	$30.30M	73.66	-$137.17M	-$1.07	N/A

Summary

Vaxcyte and Generate Biomedicines tied by winning 6 of the 12 factors compared between the two stocks.

How does Generate Biomedicines compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Generate Biomedicines (NASDAQ:GENB) are both mid-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

TG Therapeutics currently has a consensus target price of $58.60, suggesting a potential upside of 9.92%. Generate Biomedicines has a consensus target price of $25.40, suggesting a potential upside of 45.89%. Given Generate Biomedicines' stronger consensus rating and higher possible upside, analysts clearly believe Generate Biomedicines is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

58.6% of TG Therapeutics shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

TG Therapeutics has a net margin of 65.95% compared to Generate Biomedicines' net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Generate Biomedicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Generate Biomedicines	N/A	N/A	N/A

In the previous week, Generate Biomedicines had 1 more articles in the media than TG Therapeutics. MarketBeat recorded 2 mentions for Generate Biomedicines and 1 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.72 beat Generate Biomedicines' score of 0.00 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TG Therapeutics has higher revenue and earnings than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	13.24	$447.18M	$2.86	18.64
Generate Biomedicines	$30.30M	73.66	-$137.17M	-$1.07	N/A

Summary

TG Therapeutics beats Generate Biomedicines on 11 of the 16 factors compared between the two stocks.

How does Generate Biomedicines compare to Apogee Therapeutics?

Generate Biomedicines (NASDAQ:GENB) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

Generate Biomedicines has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Generate Biomedicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$30.30M	73.66	-$137.17M	-$1.07	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

In the previous week, Apogee Therapeutics had 4 more articles in the media than Generate Biomedicines. MarketBeat recorded 6 mentions for Apogee Therapeutics and 2 mentions for Generate Biomedicines. Apogee Therapeutics' average media sentiment score of 0.18 beat Generate Biomedicines' score of 0.00 indicating that Apogee Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Apogee Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Generate Biomedicines' return on equity of 0.00% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Apogee Therapeutics	N/A	-32.64%	-31.25%

79.0% of Apogee Therapeutics shares are owned by institutional investors. 24.3% of Apogee Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Generate Biomedicines currently has a consensus price target of $25.40, indicating a potential upside of 45.89%. Apogee Therapeutics has a consensus price target of $121.25, indicating a potential downside of 8.77%. Given Generate Biomedicines' stronger consensus rating and higher possible upside, equities analysts plainly believe Generate Biomedicines is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24

Summary

Generate Biomedicines beats Apogee Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Generate Biomedicines compare to Qiagen?

Generate Biomedicines (NASDAQ:GENB) and Qiagen (NYSE:QGEN) are both mid-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Generate Biomedicines presently has a consensus target price of $25.40, indicating a potential upside of 45.89%. Qiagen has a consensus target price of $43.15, indicating a potential upside of 7.65%. Given Generate Biomedicines' stronger consensus rating and higher probable upside, equities research analysts clearly believe Generate Biomedicines is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Qiagen	1 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.38

70.0% of Qiagen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Generate Biomedicines had 2 more articles in the media than Qiagen. MarketBeat recorded 2 mentions for Generate Biomedicines and 0 mentions for Qiagen. Generate Biomedicines' average media sentiment score of 0.00 equaled Qiagen'saverage media sentiment score.

Company	Overall Sentiment
Generate Biomedicines	Neutral
Qiagen	Neutral

Qiagen has a net margin of 19.16% compared to Generate Biomedicines' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Generate Biomedicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Qiagen	19.16%	14.40%	8.40%

Qiagen has higher revenue and earnings than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$30.30M	73.66	-$137.17M	-$1.07	N/A
Qiagen	$2.09B	3.95	$424.88M	$1.91	20.98

Summary

Qiagen beats Generate Biomedicines on 10 of the 15 factors compared between the two stocks.

How does Generate Biomedicines compare to Protagonist Therapeutics?

Generate Biomedicines (NASDAQ:GENB) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

In the previous week, Protagonist Therapeutics had 2 more articles in the media than Generate Biomedicines. MarketBeat recorded 4 mentions for Protagonist Therapeutics and 2 mentions for Generate Biomedicines. Protagonist Therapeutics' average media sentiment score of 0.43 beat Generate Biomedicines' score of 0.00 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protagonist Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Generate Biomedicines has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Generate Biomedicines' return on equity of 0.00% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Generate Biomedicines currently has a consensus target price of $25.40, indicating a potential upside of 45.89%. Protagonist Therapeutics has a consensus target price of $115.21, indicating a potential downside of 12.46%. Given Generate Biomedicines' higher probable upside, research analysts clearly believe Generate Biomedicines is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

98.6% of Protagonist Therapeutics shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Protagonist Therapeutics has higher revenue and earnings than Generate Biomedicines. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Generate Biomedicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$30.30M	73.66	-$137.17M	-$1.07	N/A
Protagonist Therapeutics	$46.02M	183.93	-$130.15M	-$1.81	N/A

Summary

Protagonist Therapeutics beats Generate Biomedicines on 10 of the 16 factors compared between the two stocks.

Get Generate Biomedicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GENB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GENB vs. The Competition

Export

Metric	Generate Biomedicines	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$2.23B	$3.14B	$5.21B	$12.47B
Dividend Yield	N/A	15.26%	16.10%	6.50%
P/E Ratio	-16.27	13.51	23.91	24.70
Price / Sales	73.66	2,827.42	168.49	98.61
Price / Cash	N/A	25.31	35.06	57.09
Price / Book	N/A	5.15	13.25	6.46
Net Income	-$137.17M	-$34.63M	$113.80M	$337.01M
7 Day Performance	5.71%	1.00%	0.93%	1.69%
1 Month Performance	35.28%	0.85%	1.08%	3.81%
1 Year Performance	N/A	12.21%	10.03%	23.90%

Generate Biomedicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GENB Generate Biomedicines	2.0515 of 5 stars	$17.41 flat	$25.40 +45.9%	N/A	$2.23B	$30.30M	N/A	312	Gap Down
PCVX Vaxcyte	2.0318 of 5 stars	$58.82 +1.9%	$86.00 +46.2%	+75.7%	$8.49B	N/A	N/A	160	Gap Down
TGTX TG Therapeutics	3.3666 of 5 stars	$55.50 -0.4%	$58.60 +5.6%	+43.3%	$8.47B	$616.29M	19.35	290
APGE Apogee Therapeutics	1.1305 of 5 stars	$132.70 +0.1%	$121.25 -8.6%	+179.5%	$8.21B	N/A	N/A	91	Insider Trade High Trading Volume
QGEN Qiagen	3.3587 of 5 stars	$39.44 -0.9%	$43.15 +9.4%	-21.2%	$8.13B	$2.09B	20.59	5,654

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GENB) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Generate Biomedicines (GENB) Competitors

GENB vs. PCVX, TGTX, APGE, QGEN, and PTGX

How does Generate Biomedicines compare to Vaxcyte?

Summary

How does Generate Biomedicines compare to TG Therapeutics?

Summary

How does Generate Biomedicines compare to Apogee Therapeutics?

Summary

How does Generate Biomedicines compare to Qiagen?

Summary

How does Generate Biomedicines compare to Protagonist Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GENB vs. The Competition

Generate Biomedicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Generate Biomedicines (GENB) Competitors

GENB vs. PCVX, TGTX, APGE, QGEN, and PTGX

How does Generate Biomedicines compare to Vaxcyte?

Do institutionals and insiders believe in PCVX or GENB?

Is PCVX or GENB more profitable?

Do analysts rate PCVX or GENB?

Does the media refer more to PCVX or GENB?

Which has higher valuation and earnings, PCVX or GENB?

Summary

How does Generate Biomedicines compare to TG Therapeutics?

Do analysts prefer TGTX or GENB?

Do institutionals & insiders hold more shares of TGTX or GENB?

Is TGTX or GENB more profitable?

Does the media favor TGTX or GENB?

Which has higher valuation & earnings, TGTX or GENB?

Summary

How does Generate Biomedicines compare to Apogee Therapeutics?

Which has higher valuation and earnings, GENB or APGE?

Does the media prefer GENB or APGE?

Is GENB or APGE more profitable?

Do institutionals & insiders believe in GENB or APGE?

Do analysts recommend GENB or APGE?

Summary

How does Generate Biomedicines compare to Qiagen?

Do analysts recommend GENB or QGEN?

Do institutionals and insiders believe in GENB or QGEN?

Does the media prefer GENB or QGEN?

Is GENB or QGEN more profitable?

Which has preferable earnings & valuation, GENB or QGEN?

Summary

How does Generate Biomedicines compare to Protagonist Therapeutics?

Does the media refer more to GENB or PTGX?

Is GENB or PTGX more profitable?

Do analysts recommend GENB or PTGX?

Do insiders and institutionals believe in GENB or PTGX?

Which has stronger earnings and valuation, GENB or PTGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GENB vs. The Competition

Generate Biomedicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools